Metallothionein and p-Akt proteins in oral dysplasia and in oral squamous cell carcinoma: An immunohistochemical study

Journal of Oral Pathology and Medicine

Volumn 38, Issue 8, 2009, Pages 644-650

  Pontes, H A R ^a   De Aquino Xavier, F C ^b   Da Silva, T S P ^a   Fonseca, F P ^a,c   Paiva, H B ^a   Pontes, F S C ^a   Dos Santos Pinto Jr , D ^b  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Dysplasia; Oral cancer; Oral mucosa; Oral pre cancer

Indexed keywords

METALLOTHIONEIN; PEROXIDASE; PROTEIN KINASE B;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MALE; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; POST HOC ANALYSIS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; METALLOTHIONEIN; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-AKT; REFERENCE VALUES; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 70350277398     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00787.x     Document Type: Article

References (44)

1. Lo WL, Kao SY, Chi LY, Wong YK, Chang RCS. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: Factors affecting survival. J Oral Maxillofac Surg 2003; 61: 751-758.
2. Saavedra GA, Amador VR, Camacho MEI, Romero AZ, Zepeda MAZ. Oral and pharyngeal cancer mortality rates in México, 1979-2003. J Oral Pathol Med 2008; 37: 11-17.
3. Lee JJ, Hung HC, Cheng SJ. Factors associated with underdiagnosis from incisional biopsy of oral leukoplakic lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 217-225.
4. Liu SC, Szanto K. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 2000; 36: 145-151.
5. Lee JJ, Hung HC, Cheng SJ. Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 472-480.
6. Bocharova OA, Pozharitskaya MM, Chekalina TL. Leukoplakia of oral mucosa: Pathogenesis and possible correction with phytoadaptogen. Bull Exp Biol Med 2004; 138: 578-583
7. Lim J, Kim JH, Paeng JY. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005; 58: 1199-1205.
8. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of Akt in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 2053-2059.
9. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch H. Akt proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23: 201-205.
10. Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kB, IkB Kinase α and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001; 92: 3037-3044
11. Merseburger AS, Hennenlotter J, Simon P, et al. Activation of the PKB/ Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Reports 2006; 16: 79-83.
12. Sagatys E, Garrett C, Boulware D, Kelley S, Malafa M, Cheng JQ. Activation of the serine / threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol 2007; 38: 1526-1531 (Pubitemid 47418964)
13. Cherian MG, Jayasurya A, Bay BH. Metallothionein in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
14. Gallicchio LM, Flaws JA, Fowler BA, Ioffe OB. Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev 2005; 29: 332-337.
15. Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mouri K. Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res 2000; 20(1A): 257-264
16. Cardoso SV, Barbosa HM, Candellori IM, Loyola AM, Aguiar MCF. Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch 2002; 441: 174-178
17. Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis NJ. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract 1999; 195: 809-814.
18. Miranda A, Janssen L, Duijn WV, et al. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 2002; 8: 1889-1896
19. Lee SS, Yang SF, Ho YC, Tsai CH, Chang YC. The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol 2008; 44: 180-186.
20. Barnes L, Eveson JW, Reichart PA, Sidranskiy D. World Health Organization Classification of Tumours, Pathology and Genetics of Head and Neck Tumours, 1st edn. Lyon: IARC Press, 2005.
21. Ayres M, Ayres M Jr, Ayres DL, Dos Santos AAS. BioEstat 5.0: Aplicações Estatísticas nas A ́reas das Ciências Biológicas e Médicas, 5th edn. Belém, PA: Publicações Avulsas do Mamirauá ; 2008. p. 39 (In Portuguese).
22. Wu HT, Ko SY, Fong JHJ, Chang KW, Liu TY, Kao SY. Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. J Oral Pathol Med 2008; 37: 125-131.
23. Massareli E, Liu DD, Lee JJ, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005; 104: 2430-2436.
24. Martelli AM, Faenza I, Billi AM. Intranuclear 3′ - phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 2006; 28: 1101-1107
25. Rosner M, Hanneder M, Freilinger A, Hengstschläger M. Nuclear / cytoplasmic localization of Akt activity in the cell cycle. Amino Acids 2007; 32: 341-345.
26. Luo J, Manning BD, Cantley LC. Targeting the PI3k-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003; 4: 257-261.
27. Kwon O, Kim KA, He L. Complex fromation of p65 / RelA with nuclear Akt1 for anhanced transcriptional activation of NF-κB. Biochem Biophys Res Commun 2008; 365: 771-776.
28. Brunet A, Bonni A, Zigmond MJ. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999; 96: 857-868.
29. Ahn JY, Liu X, Liu Z, et al. Nuclear Akt associates with PKC-phosphorylated Ebp-1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J 2006; 25: 2083-2095.
30. Wang R, Brattain M. Akt can be activated in the nucleus. Cell Signal 2006; 18: 1722-1731.
31. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63: 2172-2178.
32. Kaomongkolgit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/ Akt pathway in human head and neck squamous cell carcinoma cells. Oral Oncol 2008; 44: 587-594.
33. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NF-kB-dependent survival in lung cancer cells. Carcinogenesis 2005; 26: 1182-1195.
34. Lee HY, Oh SH, Woo JK, Kim WY, Pelt CSV, Price RE. Chemopreventive effects of deguelin, a novel Akt inhibitior, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005; 97: 1695-1699.
35. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
36. Endo T, Yoshikawa M, Ebara M, et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistence to platinum agents. J Gastroenterol 2004; 39: 1196-1201.
37. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG. Metallothionein expression in patients with small cell carcinoma of the lung. Cancer 2001; 92: 836-842.
38. Abdel-Mageed A, Agrawal KC. Activation of nuclear factor kB: Potential role in metallothionein-mediated mitogenic response. Cancer Res 1998; 58: 2335-2338.
39. Jin R, Huang J, Tan PH, Bay BH. Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 2004; 10: 74-79.
40. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med 2006; 231: 1516-1521.
41. Galizia G, Ferraraccio F, Lieto E, et al. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J Surg Oncol 2006; 93: 241-252.
42. Ebert MP, Günther T, Hoffmann J, et al. Expression of metallothionein II in intestinal metaplasia, dysplasia, and a gastric cancer. Cancer Res 2000; 60: 1995-2001.
43. Johann ACBR, Silveira-Jú nior JB, Souto GR, Horta MCR, Aguiar MCF, Mesquita RA. Metallothionein in oral leukoplakia Metallothionein immunoexpression in oral leukoplakia. Med Oral Patol Oral Cir Bucal 2008; 13: E156-60.
44. Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed cell carcinoma of the tongue in squamous. Eur J Cancer 1997; 33: 1860-1864.